S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
NASDAQ:SLN

Silence Therapeutics (SLN) Stock Price, News & Analysis

$25.78
+0.31 (+1.22%)
(As of 03/1/2024 ET)
Today's Range
$25.19
$26.00
50-Day Range
$16.29
$25.78
52-Week Range
$4.55
$26.70
Volume
239,264 shs
Average Volume
332,588 shs
Market Capitalization
$771.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00

Silence Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.3% Upside
$47.00 Price Target
Short Interest
Healthy
0.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Silence Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.34) to ($1.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.92 out of 5 stars

Medical Sector

443rd out of 950 stocks

Pharmaceutical Preparations Industry

199th out of 427 stocks


SLN stock logo

About Silence Therapeutics Stock (NASDAQ:SLN)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

SLN Stock Price History

SLN Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Silence Therapeutics (NASDAQ:SLN) Shares Gap Up to $23.07
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Silence Therapeutics PLC (SLN)
Morgan Stanley Keeps Their Buy Rating on Silence Therapeutics (SLN)
See More Headlines
Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/03/2024
Next Earnings (Confirmed)
3/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SLN
Fax
N/A
Employees
122
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$47.00
High Stock Price Target
$75.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+82.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-50,080,000.00
Net Margins
-151.43%
Pretax Margin
-180.03%

Debt

Sales & Book Value

Annual Sales
$21.65 million
Book Value
$0.76 per share

Miscellaneous

Free Float
29,045,000
Market Cap
$771.60 million
Optionable
Not Optionable
Beta
1.45

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Craig A. Tooman M.B.A. (Age 59)
    President & Chief Executive Officer
    Comp: $824.39k
  • Ms. Rhonda L. Hellums (Age 51)
    CFO & Secretary
    Comp: $555.51k
  • Dr. Steven J. Romano M.D. (Age 65)
    Head of Research & Development
    Comp: $46.93k
  • Dr. Marie Wikstrom Lindholm Ph.D.
    Chief Scientific Officer
  • Ms. Gem Gokmen Hopkins
    Head of IR & Corporate Communications
  • Dr. Barbara A. Ruskin J.D. (Age 64)
    Ph.D., Senior VP and Chief Intellectual Property & Innovation Officer
  • Dr. Eric Floyd M.B.A. (Age 62)
    M.S., Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance
  • Mr. J.P. Gabriel
    Chief Technical Operations Officer
  • Mr. Curtis Rambaran M.D.
    Chief Medical Officer














SLN Stock Analysis - Frequently Asked Questions

Should I buy or sell Silence Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLN shares.
View SLN analyst ratings
or view top-rated stocks.

What is Silence Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued twelve-month price targets for Silence Therapeutics' stock. Their SLN share price targets range from $20.00 to $75.00. On average, they expect the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 82.3% from the stock's current price.
View analysts price targets for SLN
or view top-rated stocks among Wall Street analysts.

How have SLN shares performed in 2024?

Silence Therapeutics' stock was trading at $17.37 at the beginning of the year. Since then, SLN shares have increased by 48.4% and is now trading at $25.78.
View the best growth stocks for 2024 here
.

Are investors shorting Silence Therapeutics?

Silence Therapeutics saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 35,100 shares, a decline of 76.9% from the January 31st total of 152,200 shares. Based on an average daily trading volume, of 195,600 shares, the days-to-cover ratio is presently 0.2 days.
View Silence Therapeutics' Short Interest
.

When is Silence Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our SLN earnings forecast
.

How can I listen to Silence Therapeutics' earnings call?

Silence Therapeutics will be holding an earnings conference call on Wednesday, March 13th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Who are Silence Therapeutics' major shareholders?

Silence Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (1.70%), Parkman Healthcare Partners LLC (0.78%), Cantor Fitzgerald L. P. (0.49%), UBS Group AG (0.23%), Citadel Advisors LLC (0.07%) and SG Americas Securities LLC (0.02%).

How do I buy shares of Silence Therapeutics?

Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLN) was last updated on 3/3/2024 by MarketBeat.com Staff